This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Multiple myeloma and malignant plasma cell neoplasms다발성 골수종 및 악성형질세포신생물 (다발성골수종)

A. Classification codesICD-10: C90 | C90.0 Multiple myeloma | C90.1 Plasma cell leukemia | C90.2 Plasmacytoma | C90.3 Solitary plasmacytoma of bone | Special Copayment Reduction V193 (copayment 5%, for 5 years from the registration date)
B. SynonymsKahler's disease, plasma cell myeloma, MM, malignant plasmacytoma, multiple myeloma (MM)
C. Adult onsetVery high — median age at diagnosis 69, extremely rare in children, onset mainly in adults aged 60 and older
Contents 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References

1. History

The history of multiple myeloma dates back to the mid-19th century. In 1845, the British physicians Henry Bence and Thomas Henry Jones discovered an unusual protein in urine, and in 1847 the chemist Henry Bence Jones systematically described the chemical properties of this protein, thereby first identifying the light chain proteinuria that would later be called 'Bence Jones protein'. This became established as the first biological marker of plasma cell proliferation.

In 1873, the Austrian pathologist von Rustizky first named bone plasma cell infiltration with multiple lesions 'multiple myeloma', and in 1889, Otto Kahler described a clinical case in detail, so it was at one time also called Kahler's disease. In the early 20th century, with the introduction of Röntgen radiographic technology, the characteristic lytic bone lesions began to be confirmed by imaging.

The turning point in the history of treatment was the introduction of the alkylating agent melphalan in 1962, after which combination with dexamethasone became the standard regimen. In 1996, the anti-myeloma effect of thalidomide was discovered, opening the era of immunomodulatory drugs (IMiD), and in 2003 the proteasome inhibitor bortezomib received FDA approval, changing the treatment paradigm. In 2005, lenalidomide was introduced, and the VRd (bortezomib-lenalidomide-dexamethasone) triplet regimen became standard. Since 2015, the anti-CD38 monoclonal antibody daratumumab and elotuzumab have been introduced, opening the era of quadruplet regimens, and since 2021, with the approval of BCMA-targeted CAR-T cell therapies (ide-cel, cilta-cel), multiple myeloma has become the hematologic cancer whose treatment is currently evolving most rapidly.

2. Causes

The exact cause of multiple myeloma has not yet been fully elucidated, but several risk factors have been identified. Age is the strongest risk factor; incidence rises sharply after age 60, and it is very rare under age 40. Racial differences are also marked: African Americans have more than twice the incidence of White people, while it is relatively low in East Asians.

Monoclonal gammopathy of undetermined significance (MGUS) is the precursor stage of multiple myeloma and progresses to myeloma at a rate of about 1% per year, while smoldering myeloma has a progression risk of 10% per year. The prevalence of MGUS reaches about 3% of the general adult population aged 50 and older.

Radiation exposure is an established risk factor; an increased risk of multiple myeloma was confirmed in the atomic bomb survivor cohort. Occupational chemical exposure — especially benzene, pesticides, and herbicides — is also known to be a risk factor, but the level of evidence is lower than for radiation. Meta-analyses have confirmed that obesity and diabetes increase the risk of myeloma by about 20%. The risk of plasmacytoma increases in immunosuppressed states (HIV infection, use of immunosuppressants after organ transplantation). In addition, with a family history, a 3.7-fold increased risk in first-degree relatives has been reported, so genetic predisposition plays some role.

Secondary myeloma can occur in patients who previously received chemotherapy or radiation therapy, but this is rare. Viral associations (EBV, HHV-8) have also been suggested, but a direct causal relationship has not been established.

3. Genetics

Multiple myeloma is characterized by complex genomic abnormalities and is broadly classified as hyperdiploid or non-hyperdiploid. Hyperdiploid myeloma (about 55%) is characterized by trisomies of odd-numbered chromosomes (3, 5, 7, 9, 11, 15, 19, 21) and has a relatively favorable prognosis.

Non-hyperdiploid myeloma is characterized mainly by translocations involving the immunoglobulin heavy chain (IGH) locus (14q32). The main translocations are as follows:

Among secondary genomic abnormalities, 17p13 deletion (TP53 deletion) is the most important high-risk factor and carries an extremely poor prognosis whether alone or combined with other abnormalities. 1q21 amplification (CKS1B) is found in about 30-40%, and increased copy number (≥4 copies) is classified as high risk. RAS mutations (KRAS, NRAS) occur in about 50%, and TP53 mutations and MYC rearrangements are also frequent at advanced stages.

R-ISS (Revised International Staging System) integrates serum β2-microglobulin, albumin, LDH, and iFISH results to stratify risk into stages I-III. From a pharmacogenomic perspective, the response rate to venetoclax alone or in combination is high when t(11;14) is present, bortezomib-based regimens are used in patients with t(4;14), and CYP2C19 polymorphisms affect the metabolism of thalidomide/lenalidomide.

4. General epidemiology

Multiple myeloma is the second most common hematologic cancer worldwide, with about 176,000 new diagnoses and 117,000 deaths per year (as of 2020). The worldwide crude incidence is about 2.1 per 100,000 population. In Korea, according to data from the Korea Central Cancer Registry of the National Cancer Center, the annual number of new multiple myeloma cases as of 2021 is about 2,100-2,200 and is increasing rapidly.

The incidence in Korea has more than doubled over the past 20 years along with population aging. The incidence is slightly higher in men (M:F ≈ 1.3:1), and the median age at diagnosis is 66-70, similar to Western countries. According to Health Insurance Review & Assessment Service (HIRA) data, myeloma-related medical costs and hospitalizations are also continuing to increase.

MGUS, the precursor stage, is found in about 1.5-3% of Koreans aged 50 and older, and smoldering myeloma accounts for about 10-15% of all myeloma diagnoses. Plasma cell leukemia is a rare subtype accounting for only 1-2% of all myeloma, but its prognosis is extremely poor. Solitary plasmacytoma accounts for 3-5% of the total, and long-term remission can be achieved with radiation therapy.

5. Pathophysiology

The development of multiple myeloma is understood as a process of multi-step oncogenesis. Once the first genomic abnormality occurs in a normal plasma cell, it progresses sequentially from MGUS → smoldering myeloma → symptomatic myeloma.

Typical initiating events are IGH translocations arising during somatic hypermutation or class switch recombination in germinal center B cells. t(4;14) activates FGFR3, and MMSET modifies the epigenome through histone H3K36 methylation. t(11;14) overexpresses CCND1, promoting the G1/S cell cycle transition.

The bone marrow microenvironment plays an important role in progression from MGUS to myeloma. Contact-dependent survival signals are activated through VLA-4/VCAM-1 and CD44/hyaluronic acid binding between stromal cells and plasmacytoma cells, and cytokines such as IL-6, VEGF, and IGF-1 promote plasma cell proliferation and survival. Osteoclast-activating factors (RANKL, MIP-1α) increase, promoting bone destruction.

Accumulation of secondary genomic abnormalities — RAS mutations, MYC abnormalities, TP53 deletion, NF-κB pathway activation — drives the transition from MGUS to symptomatic myeloma. NF-κB pathway activation occurs in about 40% of myelomas and contributes to inhibition of apoptosis and immune evasion. Monoclonal immunoglobulin (M protein) deposits in the renal tubules, causing nephrotoxicity, and can lead to light chain amyloidosis.

6. Symptoms

The clinical symptoms of multiple myeloma are summarized by the CRAB criteria: Calcium elevation (hypercalcemia), Renal insufficiency, Anemia, Bone lesions.

Bone pain is the most common symptom, occurring in about 70% of patients, and is characterized by persistent, dull pain in the thoracic and lumbar spine. Pathologic fractures due to lytic bone lesions, especially vertebral compression fractures, occur in 20-40% and can lead to neurologic complications (spinal cord compression, paralysis). Fatigue and weakness are due to anemia (hemoglobin <10 g/dL) and are reported in 60-70%.

Hypercalcemia (serum calcium >11 mg/dL or >1 mg/dL above the upper limit of normal) causes nausea, vomiting, constipation, polyuria, confusion, drowsiness, and so on. Renal insufficiency is present in about 20-30% at diagnosis and is caused by light-chain tubular injury (cast nephropathy), dehydration, hypercalcemia, NSAID overuse, and so on. Susceptibility to infection is due to reduced normal immunoglobulins (immune paresis) and neutropenia, and pneumococcal pneumonia is the most common infection. Rarely, hyperviscosity syndrome develops, with headache, visual disturbance, and a bleeding tendency.

7. Signs

There are few specific signs on physical examination, but the following findings are important. Pallor (anemia), thoracic and lumbar spine tenderness (bone lesions), and altered consciousness or coma (hypercalcemia, hyperviscosity syndrome) may be present. When a plasmacytoma arises in the chest wall or skull, it appears as a palpable mass. With spinal cord compression, lower limb weakness, sensory loss, and bladder and bowel dysfunction may occur.

On laboratory findings, M protein (M-spike) is detected on serum protein electrophoresis (SPEP), and the type of monoclonal immunoglobulin (IgG, IgA, IgM, light chain only, etc.) is identified by immunofixation electrophoresis (IFE). Serum free light chain assay (SFLC) shows an abnormal kappa:lambda ratio. Elevated β2-microglobulin and LDH suggest high risk and advanced stage. Elevated serum calcium, elevated creatinine, and decreased serum albumin often accompany these. The complete blood count shows normocytic normochromic anemia and rouleaux formation. On plain radiographs, 'punched-out' lytic lesions of the skull, spine, and ribs are characteristic, and whole-body low-dose CT or PET-CT is more sensitive for evaluating bone lesions.

8. Screening

Standard screening for multiple myeloma in the general population is not currently recommended. However, follow-up of the following high-risk groups is important.

Follow-up of MGUS patients: patients diagnosed with MGUS are re-evaluated after the first 6 months; thereafter, low-risk MGUS (IgG type, M protein <1.5 g/dL, normal serum free light chain ratio) is monitored every 2-3 years and high-risk MGUS every 6-12 months. At each visit, serum protein electrophoresis, free light chain assay, complete blood count, creatinine, and calcium are measured.

Surveillance of smoldering myeloma: the low-risk group is followed every 6 months and the high-risk group (Mayo or IMWG risk criteria) every 3-4 months, and participation in clinical trials is considered. In recent clinical studies such as MAIA and AQUILA, daratumumab monotherapy for high-risk smoldering myeloma showed a delay in progression, and prospective treatment is being discussed.

As initial diagnostic testing, the three-test combination of SPEP + IFE + SFLC has the highest sensitivity; combining these three tests can detect more than 99% of myelomas. In people aged 50 and older with unexplained anemia, renal insufficiency, hypercalcemia, bone pain, or recurrent infections, M protein screening must be performed.

9. Diagnosis

The diagnosis of multiple myeloma rests on three pillars: bone marrow examination, serum and urine protein tests, and imaging. According to the 2016 IMWG (International Myeloma Working Group) criteria, myeloma requiring treatment is diagnosed when bone marrow plasma cells are ≥10% or there is a biopsy-proven plasmacytoma, plus one or more myeloma-defining events (MDE).

MDE (Myeloma Defining Events): CRAB criteria + SLiM criteria (bone marrow plasma cells ≥60%, serum free light chain ratio ≥100, more than 1 focal lesion on MRI). Bone marrow morphology is used to measure the plasma cell percentage and confirm the immunophenotype (CD38+, CD138+, CD19−, CD45−/weakly positive). Bone marrow cytogenetics: iFISH testing (t(4;14), t(14;16), t(11;14), del(17p), 1q21 amplification, del(13q)) is essential.

Serum tests: SPEP, IFE, SFLC (serum free light chains), quantitative immunoglobulins (IgG, IgA, IgM), β2-microglobulin, LDH, serum albumin, creatinine, calcium. Urine tests: 24-hour urine protein electrophoresis (UPEP), urine immunofixation electrophoresis (UIFE). Imaging: whole-body low-dose CT (recommended, superior to plain radiographs), PET-CT (useful for extramedullary lesions, treatment response assessment, and MRD assessment), MRI (evaluation of spinal lesions and spinal cord compression). Response criteria are classified as sCR, CR, VGPR, PR, SD, and PD according to the IMWG response criteria, and confirmation of MRD (minimal residual disease) negativity by next-generation flow cytometry or next-generation sequencing is used as a predictor of long-term survival.

Staging uses the R-ISS (Revised International Staging System): stage I (β2-MG <3.5 mg/L, albumin ≥3.5 g/dL, standard-risk FISH, normal LDH), stage II (neither I nor III), stage III (β2-MG ≥5.5 mg/L + high-risk FISH or high LDH).

10. Treatment

Treatment of multiple myeloma depends on transplant eligibility, and in all patients the goal is deep response (MRD negativity) and prolonged long-term survival.

Transplant-eligible (TE) patients

Induction therapy: daratumumab-VRd (bortezomib-lenalidomide-dexamethasone, GRIFFIN/PERSEUS trials) or isatuximab-VRd (IsaVRd, MAIA lineage) has become the standard quadruplet regimen. In the PERSEUS trial, Dara-VRd showed markedly superior results to VRd in the 3-year sustained MRD-negativity rate. After 4-6 cycles of induction, autologous stem cell transplantation (ASCT) is performed, and post-transplant lenalidomide maintenance (indefinitely or until disease progression) prolongs PFS and OS.

Transplant-ineligible (TNE) patients

Daratumumab-Rd (lenalidomide-dexamethasone, MAIA trial) is established as the standard first-line regimen for newly diagnosed TNE patients. In the MAIA trial, a median PFS of 61 months (vs. 34 months with Rd) and improved OS were reported. Bortezomib-based regimens (VMP, daratumumab-VMP) are also alternatives.

Relapsed/refractory myeloma (RRMM)

Various combinations of carfilzomib, pomalidomide, isatuximab, daratumumab, panobinostat, elotuzumab, and others are used. As BCMA-targeted therapies, the antibody-drug conjugate belantamab mafodotin, bispecific antibodies (teclistamab, elranatamab, talquetamab), and the CAR-T cell therapies idecabtagene vicleucel (ide-cel, bb2121) and ciltacabtagene autoleucel (cilta-cel, CARVYKTI) are innovative treatment options. In t(11;14)-positive patients, combination with venetoclax is considered. Under Korean National Health Insurance, bortezomib (first line), lenalidomide (second line or later), and daratumumab (second line or later, recently expanded to first line) are covered, and the Korean Society of Hematology myeloma practice guidelines are referenced.

11. Prognosis

The prognosis of multiple myeloma has improved dramatically over the past 20 years with the introduction of new drugs. In the early 2000s, the 5-year survival rate was about 30-35%, but recently the 5-year survival rate of newly diagnosed patients has reached 60% or more (65-70% in some studies). Median OS in R-ISS stage I patients is 8-12 years or more depending on the report, while in R-ISS stage III it is about 3-5 years.

The factor with the greatest impact on prognosis is cytogenetics. Patients with high-risk abnormalities such as t(4;14), del(17p), t(14;16), and 1q21 combined abnormalities have markedly shorter median PFS. Achieving MRD (minimal residual disease) negativity is the strongest predictor of OS and PFS; MRD-negative patients have 2-3-fold longer PFS than MRD-positive patients. Whether renal function can improve (reversible renal failure) also affects prognosis.

In the current era of quadruplet regimens, a substantial proportion of standard-risk patients survive 10 years or more, and with the introduction of BCMA-targeted CAR-T therapies, median PFS after the 3rd-4th line has improved markedly compared with previous treatments (CARTITUDE-1: median PFS 34 months). Long-term prognostic data for Korean patients continue to accumulate in Korean Society of Hematology registry studies.

12. Prevention

There is as yet no established method for primary prevention of multiple myeloma. However, the risk of developing it can be partly reduced by controlling the following risk factors. Obesity management: maintaining a normal body weight can lower myeloma risk by 20% or more, and maintaining metabolic health through regular exercise and a balanced diet is important. Minimizing radiation exposure: reduce unnecessary medical radiation exposure, and occupational radiation workers should strictly follow safety rules. Avoiding exposure to hazardous chemicals: minimize occupational exposure to potentially carcinogenic substances such as benzene, pesticides, and herbicides.

Management of MGUS patients is the most important means of secondary prevention. MGUS patients should have regular follow-up so that progression to myeloma is detected early and the timing of treatment is not missed. Patients with high-risk smoldering myeloma can have the efficacy and safety of preventive treatment evaluated through participation in clinical studies. In the AQUILA trial, daratumumab monotherapy significantly delayed progression to active myeloma in patients with high-risk smoldering myeloma. In addition, as periodic immune care, infectious complications are prevented with pneumococcal and influenza vaccination, and in patients already receiving myeloma treatment, acyclovir is recommended for herpes prophylaxis.


13. References

  1. Kumar SK, Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2024;99(9):1802-1830.
  2. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086-1107.
  3. Moreau P, et al. CASSIOPEIA: Daratumumab plus VTd in newly diagnosed myeloma. N Engl J Med. 2019;380(22):2104-2115.
  4. Facon T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (MAIA). N Engl J Med. 2019;380(22):2104-2115.
  5. Munshi NC, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-716.
  6. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101-119.
  7. Korean Society of Hematology. Clinical practice guidelines for multiple myeloma 2023. Seoul: Korean Society of Hematology.
  8. National Cancer Center. Korea Central Cancer Registry statistics. 2022 cancer registry statistics. Ministry of Health and Welfare (MOHW)·National Cancer Center. 2024.
  9. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma. Br J Haematol. 2003;121(5):749-757.
  10. Palumbo A, et al. Revised International Staging System for Multiple Myeloma. J Clin Oncol. 2015;33(26):2863-2869.